Continuous glucose monitor metrics from five studies identify participants at risk for type 1 …

11.02.2025 | Article

verfasst von: Peter Calhoun, Charles Spanbauer, Andrea K. Steck, Brigitte I. Frohnert, Mark A. Herman, Bart Keymeulen, Riitta Veijola, Jorma Toppari, Aster Desouter, Frans Gorus, Mark Atkinson, Darrell M. Wilson, Susan Pietropaolo, Roy W. Beck

Erschienen in: Diabetologia

Einloggen, um Zugang zu erhalten Abstract Aims/hypothesis

We aimed to assess whether continuous glucose monitor (CGM) metrics can accurately predict stage 3 type 1 diabetes diagnosis in those with islet autoantibodies (AAb).

Methods

Baseline CGM data were collected from participants with ≥1 positive AAb type from five studies: ASK (n=79), BDR (n=22), DAISY (n=18), DIPP (n=8) and TrialNet Pathway to Prevention (n=91). Median follow-up time was 2.6 years (quartiles: 1.5 to 3.6 years). A participant characteristics-only model, a CGM metrics-only model and a full model combining characteristics and CGM metrics were compared.

Results

The

Dieser Beitrag wurde original veröffentlicht auf: link zum Beitrag